Australian Indigenous model of mental healthcare based on transdiagnostic cognitive-behavioural therapy co-designed with the Indigenous community: protocol for a randomised controlled trial (vol 6, e33, 2020)

被引：0

作者：

Toombs, Maree

Nasir, Bushra

Kisely, Steve

Kondalsamy-Chennakesavan, Srinivas

Hides, Leanne

Gill, Neeraj

Beccaria, Gavin

Brennan-Olsen, Sharon

Butten, Kaley

Nicholson, Geoffrey

机构：

[1] Indigenous Health, Rural Clinical School, Faculty of Medicine, University of Queensland

[2] Rural Clinical School, Faculty of Medicine, University of Queensland

[3] Faculty of Medicine, University of Queensland

[4] School of Psychology, Faculty of Health and Behavioural Sciences, University of Queensland

[5] Rural Clinical School, Faculty of Medicine, University of Queensland, School of Medicine, Griffith University

[6] School of Psychology and Counselling, University of Southern Queensland

[7] Department of Medicine-Western Health, University of Melbourne

[8] Institute of Health and Biomedical Innovation, Centre for Children’s Health Research, Queensland University of Technology

来源：

BJPSYCH OPEN | 2020年 / 6卷 / 03期

基金：

英国医学研究理事会; 澳大利亚国家健康与医学研究理事会;

关键词：

CBT; transdiagnostic therapy; Indigenous; depressive disorders;

D O I：

10.1192/bjo.2020.26

中图分类号：

R749 [精神病学];

学科分类号：

100205 ;

摘要：

Background A four- to seven-fold increase in the prevalence of current mood, anxiety, substance use and any mental disorders in Indigenous adults compared with non-Indigenous Australians has been reported. A lifetime prevalence of major depressive disorder was 23.9%. High rates of comorbid mental disorders indicated a transdiagnostic approach to treatment might be most appropriate. The effectiveness of psychological treatment for Indigenous Australians and adjunct Indigenous spiritual and cultural healing has not previously been evaluated in controlled clinical trials. Aims This project aims to develop, deliver and evaluate the effectiveness of an Indigenous model of mental healthcare (IMMHC). Trial registration: ANZCTR Registration Number: ACTRN12618001746224 and World Health Organization Universal Trial Number: U1111-1222-5849. Method The IMMHC will be based on transdiagnostic cognitive–behaviour therapy co-designed with the Indigenous community to ensure it is socially and culturally appropriate for Indigenous Australians. The IMMHC will be evaluated in a randomised controlled trial with 110 Indigenous adults diagnosed with a current diagnosis of depression. The primary outcome will be the severity of depression symptoms as determined by changes in Beck Depression Inventory-II score at 6 months post-intervention. Secondary outcomes include anxiety substance use disorder and quality of life. Outcomes will be assessed at baseline, 6 months post-intervention and 12 months post-intervention. Results The study design adheres to the Consolidated Standards of Reporting Trials (CONSORT) statement recommendations and CONSORT extensions for pilot trials. We followed the Standard Protocol Items for Randomised Trials statement recommendations in writing the trial protocol. Conclusions This study will likely benefit participants, as well as collaborating Aboriginal Medical Services and health organisations. The transdiagnostic IMMHC has the potential to have a substantial impact on health services delivery in the Indigenous health sector. © The Author(s) 2020.

引用

页数：1